Karyopharm Therapeutics Inc (NASDAQ:KPTI) insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $12.50, for a total transaction of $125,000.00. Following the transaction, the insider now directly owns 723,510 shares of the company’s stock, valued at approximately $9,043,875. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sharon Shacham also recently made the following trade(s):

  • On Monday, January 8th, Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.08, for a total transaction of $100,800.00.
  • On Thursday, December 7th, Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.39, for a total transaction of $103,900.00.

Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) opened at $13.06 on Friday. Karyopharm Therapeutics Inc has a 52 week low of $7.48 and a 52 week high of $14.63.

A number of institutional investors and hedge funds have recently bought and sold shares of KPTI. Teacher Retirement System of Texas bought a new stake in Karyopharm Therapeutics in the fourth quarter valued at $115,000. Voya Investment Management LLC increased its stake in Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after purchasing an additional 4,444 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in Karyopharm Therapeutics in the second quarter valued at $136,000. The Manufacturers Life Insurance Company increased its stake in Karyopharm Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after purchasing an additional 5,586 shares in the last quarter. Finally, ProShare Advisors LLC increased its stake in Karyopharm Therapeutics by 8.0% in the second quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock valued at $246,000 after purchasing an additional 2,021 shares in the last quarter. 58.02% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently weighed in on KPTI. BidaskClub raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. ValuEngine raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday. Cantor Fitzgerald reissued a “buy” rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, January 25th. HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, December 12th. Finally, began coverage on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. They set a “buy” rating and a $23.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. Karyopharm Therapeutics has an average rating of “Buy” and an average target price of $17.33.

COPYRIGHT VIOLATION NOTICE: “Karyopharm Therapeutics Inc (KPTI) Insider Sells $125,000.00 in Stock” was published by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/02/10/karyopharm-therapeutics-inc-kpti-insider-sells-125000-00-in-stock.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.